First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer Meeting Abstract
| Authors: | Moore, K. N.; Bouberhan, S.; Hamilton, E. P.; Liu, J. F.; O'Cearbhaill, R. E.; O'Malley, D. M.; Papadamitriou, K.; Schröder, D.; Van N., Els; Yoo, S. Y.; Peterman, M. J.; Goncalves, P. H.; Schmidt, T.; Zhu, M.; Lowy, I.; Uldrick, T. S.; Miller, E. |
| Abstract Title: | First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS5624 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS5624 -- Meeting was also available virtually -- Source: Cinahl |
